Lack of association between dopamine D2 receptor gene Cys311 variant and schizophrenia

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 67, Issue 2, 1996, Pages 208-211

  Tanaka, Toshihisa ^a   Igarashi, Shuichi ^a   Onodera, Osamu ^a   Tanaka, Hajime ^a   Fukushima, Noboru ^a   Takahashi, Makoto ^a   Kameda, Kensuke ^a   Tsuji, Shoji ^a   Ihda, Shin ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Dopamine d2 receptor cys311 variant; Schizophrenia in the Japanese population

Indexed keywords

DOPAMINE 2 RECEPTOR; SERINE;

ALLELISM; ARTICLE; DISEASE ASSOCIATION; GENETIC LINKAGE; HUMAN; JAPAN; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYSTEINE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 0029991136     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19960409)67:2<208::AID-AJMG12>3.0.CO;2-N     Document Type: Article

References (24)

1. Andén NE, Butscher SG, Corrodi H, Fuxe K, Ungerstedt U (1970): Receptor activity and turnover of dopamine and noradrenaline after neuroleptcs. Eur J Pharmacol 11:303-314.
2. American Psychiatric Association (1987): "Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised (DSM-III-R)." Washington, DC, American Psychiatric Association.
3. Arinami T, Itokawa M, Eguchi H, Tagaya H, Yanao S, Shimizu H, Hamaguchi H, Toru M (1994): Association of dopamine D2 receptor molecular variant with schizophrenia Lancet 343:703-704.
4. Asherson P, Williams N, Roberts E, McGuffin M, Owen M (1994): DRD2 Ser311/Cys311 polymorphism in schizophrenia [Letters]. Lancet 343:1045.
5. Cohen J (1977): "Statistical Power Analysis for the Behavioral Science." New York. Academic Press.
6. Coon H, Byerley W, Holik J, Hoff M, Myles-Worsley M, Lannfelt L, Sokoloff P, Schwartz JC, Waldo M, Freeman R, Plaetke R (1993): Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am J Hum Genet 52:327-334.
7. Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D, Blum K, Noble EP, Kranzier HR, O'Malley S, Hamer DH, Whitsitt F, Rao P, DeLisi LE, Virkkunen M, Linnoila M, Goldman D, Gershon ES (1994): No structural mutation in the dopamine D2 receptor genen in alcoholism or schizophrenia. JAMA 271.204-208.
8. Gill M, McGuffin P, Parfitt E, Mant R, Asherson P, Callier D, Vallada H, Powell J, Shaikh S, Taylor C, Sargeant M, Clements A, Nanko S, Takazawa N, Lleweellyn D, Williams J, Whatly S, Murray R, Owen M (1993): A linkage study of schizophrenia with DNA markers from the long arm of chromosome 11. Psychol Med 23:27-44.
9. Gottesman II, Shields J (1982): "Schizophrenia: The Epigenetic Puzzle." Cambridge: Cambridge University Press.
10. Hattori M, Nanko S, Dai XY, Fukuda R, Kazamatsuri H (1994): Mismatch PCR RFLP detection of DRD2 Ser311 Cys polymorphism and schizophrenia. Biochem Biophys Res Commun 202:757-763.
11. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M (1993): A structural polymorphism of human dopamine D2 receptor, D2(Ser311→Cys). Biochem Biophys Res Commun 196:1369-1375
12. Janowsky DA, Davis JM (1976): Methylphenidate. dextroamphetamine, and levamphetamine: Effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304-308.
13. Krawiecka M, Goldberg D, Vaughan M (1977): A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiat Scand 55:299-308.
14. 311 mutation in schizophrenia. Psychiatric Genet 4:229-230.
15. Lee T, Seeman P, Tourtellotte WW, Farley IJ, Hornykiewicz O (1978): Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274:897-900.
16. McGuffin P (1988): Genetics of schizophrenia. In Bebbington P, McGuffin P (eds): "Schizophrenia, The Major Issues." London. Heinemann Medical, pp. 107-126.
17. Moises HW, Gelernter J, Giuffra LA, Zarcone V, Wetterberg L, Civelli O, Kidd KK, Cavilli-Sforza LL, Grandy DK, Kennedy JL, Vinogradov S, Maver J, Litt M, Sjogren B (1991): No linkage between D2 dopamine receptor gene region and schizophrenia. Arch Gen Psychiatry 48:643-647.
18. Nanko S, Hattori M, Dai XY, Fukuda R, Kazamatsuri H (1994): DRD2 Ser311/Cys311 polymorphism in schizophrenia [Letters]. Lancet 343:1044.
19. Nöthen MM, Wildenauer D, Cichon S, Albus M, Maier W, Minges J, Lichtermann D, Bondy B, Rietschel M, Körner J, Fimmers R, Propping P (1994): Dopamine D2 receptor molecular variant and schizophrenia [Letters]. Lancet 343:1301-1302.
20. Seeman P, Wong M, Lee T (1974): Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers. Fed Proc 33:246.
21. Seeman P, Lee T, Chau-Wong M, Wong K (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719.
22. Shaikh S, Collier D, Arranz M, BallD, Gill M, Kerwin R (1994): DRD2 Ser311/Cys311 polymorphism in schizophrenia [Letters]. Lancet 343:1045-1046.
23. Snyder SH (1973): Amphetamine psychosis: A 'model' schizophrenia mediated by catecholamines. Am J Psychiatry 130:61-66.
24. Sobell J, Sigurdson DC, Heston L, Sommer S (1994): S311C DRD2 variant: No association with schizophrenia [Letters]. Lancet 344: 621-622.